Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Enhanced detection of hydrogen sulfide generated in cell culture using an agar trap method.

Kartha RV, Zhou J, Hovde LB, Cheung BW, Schröder H.

Anal Biochem. 2012 Apr 1;423(1):102-8. doi: 10.1016/j.ab.2012.01.001. Epub 2012 Jan 10.

PMID:
22274539
2.

Frequency of 1st- and 2nd-step topoisomerase mutations in Streptococcus pneumoniae following levofloxacin and moxifloxacin exposure.

Hovde LB, Simonson DA, Rotschafer JC.

Diagn Microbiol Infect Dis. 2008 Mar;60(3):295-9. Epub 2007 Nov 28.

PMID:
18053674
3.

In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.

Schafer J, Hovde LB, Simonson D, Rotschafer JC.

Diagn Microbiol Infect Dis. 2008 Feb;60(2):155-61. Epub 2007 Oct 29.

PMID:
17910998
5.

Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.

Kroeger LA, Hovde LB, Mitropoulos IF, Schafer J, Rotschafer JC.

Antimicrob Agents Chemother. 2007 Sep;51(9):3431-3. Epub 2007 Jun 18.

6.

Consistent rates of kill of Staphylococcus aureus by gentamicin over a 6-fold clinical concentration range in an in vitro pharmacodynamic model (IVPDM).

Schafer JA, Hovde LB, Rotschafer JC.

J Antimicrob Chemother. 2006 Jul;58(1):108-11. Epub 2006 May 30.

PMID:
16735429
7.

Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.

Hermsen ED, Hovde LB, Konstantinides GN, Rotschafer JC.

Antimicrob Agents Chemother. 2005 Apr;49(4):1633-5.

9.

Dynamic analysis of peritoneal dialysis associated peritonitis.

Hotchkiss JR, Hermsen ED, Hovde LB, Simonson DA, Rotschafer JC, Crooke PS.

ASAIO J. 2004 Nov-Dec;50(6):568-76.

PMID:
15672790
10.

Pharmacodynamics of pulse dosing versus standard dosing: in vitro metronidazole activity against Bacteroides fragilis and Bacteroides thetaiotaomicron.

Ibrahim KH, Gunderson BW, Hermsen ED, Hovde LB, Rotschafer JC.

Antimicrob Agents Chemother. 2004 Nov;48(11):4195-9.

11.
12.

Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumoniae.

Hovde LB, Rotschafer SE, Ibrahim KH, Gunderson B, Hermsen ED, Rotschafer JC.

Diagn Microbiol Infect Dis. 2003 Apr;45(4):265-7.

PMID:
12729997
13.

Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model.

Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC.

Antimicrob Agents Chemother. 2003 Mar;47(3):905-9.

14.
15.

Microbiologic effectiveness of time- or concentration-based dosing strategies in Streptococcus pneumoniae.

Ibrahim KH, Hovde LB, Ross G, Gunderson B, Wright DH, Rotschafer JC.

Diagn Microbiol Infect Dis. 2002 Nov;44(3):265-71.

PMID:
12493174
16.

Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions.

Wright DH, Gunderson BW, Hovde LB, Ross GH, Ibrahim KH, Rotschafer JC.

Antimicrob Agents Chemother. 2002 May;46(5):1561-3.

17.
18.

Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.

Peterson ML, Hovde LB, Wright DH, Brown GH, Hoang AD, Rotschafer JC.

Antimicrob Agents Chemother. 2002 Jan;46(1):203-10.

19.

Comparison of once-daily versus twice-daily administration of cefdinir against typical bacterial respiratory tract pathogens.

Ross GH, Hovde LB, Ibrahim KH, Ibrahim YH, Rotschafer JC.

Antimicrob Agents Chemother. 2001 Oct;45(10):2936-8.

20.

Fluoroquinolone resistance in anaerobic bacteria following exposure to levofloxacin, trovafloxacin, and sparfloxacin in an in vitro pharmacodynamic model.

Ross GH, Wright DH, Hovde LB, Peterson ML, Rotschafer JC.

Antimicrob Agents Chemother. 2001 Jul;45(7):2136-40.

21.

Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.

Peterson ML, Hovde LB, Wright DH, Hoang AD, Raddatz JK, Boysen PJ, Rotschafer JC.

Antimicrob Agents Chemother. 1999 Sep;43(9):2251-5.

Supplemental Content

Loading ...
Support Center